RxDoctor Payments Data

Tarkeshwar Tiwary, MD

Pulmonary Disease · Chambersburg, PANPI 1639469950

Payments from drug & device makers

$4,253in general payments, 2019–2025

Across 21 payments — averaging $202.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$4K
  • Olympus Corporation Of The Americas$406
  • Actelion Pharmaceuticals US, Inc.$66
  • Ceribell, Inc.$42
  • Inspire Medical Systems, Inc.$29
  • Boehringer Ingelheim$25
  • plus $31 from 2 others

What the payments were for

  • Travel & lodging$60914%
  • Food & beverage$64415%
  • Education$3,00071%

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,253 in reported general payments places this provider in the 65th percentile of 703 pulmonary disease providers in Pennsylvania.

See all pulmonary disease providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$138,873
Medicare patients
532
Services billed
1,980

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter429$375,596
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr254$132,775
Breo ElliptaFluticasone/Vilanterol103$50,263
Incruse ElliptaUmeclidinium Bromide106$41,304
Combivent RespimatIpratropium/Albuterol Sulfate52$29,763
Spiriva RespimatTiotropium Bromide41$24,749
Breztri AerosphereBudesonide/Glycopyr/Formoterol30$22,635
Arnuity ElliptaFluticasone Furoate61$21,644
Spiriva HandihalerTiotropium Bromide17$20,055
Fluticasone-SalmeterolFluticasone Propion/Salmeterol99$18,005
Albuterol Sulfate HfaAlbuterol Sulfate350$12,308
SymbicortBudesonide/Formoterol Fumarate25$10,154
Ventolin HfaAlbuterol Sulfate89$7,087
Atrovent HfaIpratropium Bromide14$5,929
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate12$2,769

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimCombivent Respimat, Spiriva Respimat$25$54,51193 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 703 pulmonary disease providers in Pennsylvania.

Other pulmonary disease in Chambersburg

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →